The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.
The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms. Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).
Study Type
OBSERVATIONAL
Enrollment
1,389
Visual Analog Scale (VAS)
Efficacy of the drug, measured by a Visual Analog Scale (VAS) Scale ranged from 0(=best, no pain) to 10(worst, intolerable pain) The VAS was filled by the patient.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Tolerability of the Drug
Tolerability assessment of medical personnel End of study could by after 2 (visit 2) or after 4 weeks (Visit3). It was measured by a score: * very well tolerated (no side effects) * moderately tolerated (mild side effects) * poorly tolerated (marked side effects)
Time frame: after end of study
Pain at Rest
Number of patient (in %) with an improvement of pain at rest between V1 and V2 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Pain in Movement
Number of patients (in %) with an improvement of pain in movement between V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Pain After Rest
Number of patients (in %) with an improvement of pain after rest between V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Pain on Weight-bearing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients (in%) with an improvement of pain on weight-bearing between V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Morning Stiffness
Number of patients (in%) with an improvement of morning stiffness between V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Tenderness
Number of patients (in%) with an improvement of tenderness between V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Antalgic Position
Number of patients (in%) with an improvement of antalgic position V1 and V3 / V1 and V3 / V2 and V3 A four-point scale (0=not present, 1=slightly, 2=moderate, 3=severe) was used to record symptom severity before the beginning, during treatment and at the end of the observation period.
Time frame: Beginning (Visit 1) and after 2 (visit 2) + 4 weeks (Visit3)
Acceptance of the Drug
Number of patients with good (patient was satisfied with the treatment, there was nothing to complain about) or poor (patient was not satisfied with the treatment, there were ADRs or other reasons) acceptance.
Time frame: from enrollment until completion